A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...

Eli Lilly and Company has announced new long-term data from the ADjoin extension study, demonstrating that EBGLYSS ...

BioAge Labs stock rallied Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity ...

To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.

Eli Lilly & Co. closed $48.10 short of its 52-week high ($972.53), which the company achieved on August 22nd.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 594.50% and ...

An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...

Eli Lilly and Company (NYSE: LLY) announced these new long-term results from the ADjoin long-term extension study, which will be presented at the European Academy of Dermatology and Venereology ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.